PASG is expected to report earnings to fall 27.10% to -22 cents per share on February 27
Q4'24
Est.
$-0.23
Q3'24
Missed
by $0.08
Q2'24
Beat
by $0.05
Q1'24
Beat
by $0.05
Q4'23
Beat
by $0.09
The last earnings report on November 13 showed earnings per share of -31 cents, missing the estimate of -23 cents. With 3.17M shares outstanding, the current market capitalization sits at 40.77M.
a genetic medicines company, which focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options